Biogen Idec (BIIB) Says AVONEX More Cost Effective to Other Interferon Therapies for Multiple Sclerosis
More News related to BIIB
- Biogen Idec to Report Second Quarter 2009 Financial Results on July 16, 2009
- Biogen Idec (BIIB) volatility low into JNJ $1B investment in Elan
- Leerink Swann Upgrades Acorda Therapeutics (ACOR) Two-Notches to Outperform
- Acorda (ACOR) CEO On CNBC
- Acorda (ACOR) Enters License Agreement With Biogen Idec (BIIB) For Fampridine-SR Outside the U.S.
More News related to Corporate News
- Xerox (UK) Limited and The Danwood Group Announce the Creation of Strategic Partnership
- Elron Electronic (ELRN) to Negotiate with Clal Industries and DIC Related to Elron's 15% Interest in NetVision
- OYO Geospace (OYOG) Receives $4.3 Million Order
- RADA Electronic Industries (RADA) Announces $3.2 Million in Follow-On Orders
- NetSol Tech. (NTWK) Selected by Netherlands-Based Company to Implement Wholesale Finance System
Biogen Idec Inc. (NASDAQ: BIIB) announced that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments.
Using a comprehensive analysis of medical and pharmacy costs, the results of the research concluded that patients treated with AVONEX, the most prescribed MS therapy worldwide, have the lowest total one-year cost to a health plan when compared to other interferon beta treatments.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
